Coronary/Structural Heart

Abbott Receives CE Mark for Next-Generation MitraClip™ Heart Valve Repair Device to Treat Mitral Regurgitation

– CE Mark for MitraClip G4 offers physicians an innovative next-generation system with more options for mitral valve repair using proven clip-based technology – MitraClip is a first-of-its-kind transcatheter mitral valve therapy, now on its fourth generation, improving further on MitraClip’s history as a safe and effective treatment option ABBOTT […]

ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19

WESTMINSTER, Colo., Sept. 21, 2020 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) under the Coronavirus Treatment Acceleration Program (CTAP) to evaluate AB201 […]

Compelling New Research Links Increased Omega-3 Intake to Improved Cardiovascular Outcomes

Study published in Mayo Clinic Proceedings supports multiple cardiovascular risk reductions SALT LAKE CITY, Sept. 17, 2020 /PRNewswire/ — A new study, the most comprehensive analysis of the role of omega-3 dosage on cardiovascular prevention to date, provides compelling evidence for consuming more EPA and DHA (eicosapentaenoic acid and docosahexaenoic acid, respectively) […]

VitalConnect Announces Initiation of TELESTAR-TAVR Clinical Study

Study will evaluate the impact of remote patient monitoring on clinical outcomes, readmission rates, and patient satisfaction following a transcatheter aortic valve replacement procedure SAN JOSE, Calif.–(BUSINESS WIRE)–VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, announced today that it has begun the TELESTAR-TAVR clinical study (Deployment of Telemedicine […]

Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH)

CAMBRIDGE, Mass. & PARMA, Italy–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi Farmaceutici S.p.A., an international research-focused healthcare group (Chiesi Group), today announced a collaboration aimed at the discovery and development […]

Corventive Health to Deliver American College of Cardiology’s Evidence-Based Content in its Innovative Cardiac Care Solutions

Corventive Now Delivers Evidence-Based Content to Enhance Patient Care. NEWTOWN, Pa., Sept. 15, 2020 /PRNewswire/ — Corventive Health, a provider of cloud-based and AI technology solutions, announced its plan to integrate American College of Cardiology (“ACC”) evidence-based content into its innovative cardiac solutions. Incorporating ACC clinical content enables Corventive to deliver insights designed […]

US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack

– FDA Fast Track designation facilitates the development of potential new therapies that treat serious conditions and fulfill an unmet medical need – This Fast Track designation for empagliflozin emphasizes the urgent need for potential treatments that may improve outcomes following an acute myocardial infarction, more commonly known as a […]

Low awareness of serious but treatable heart condition could be putting Canadian lives at risk

Heart valve disease is a common, serious but treatable condition, often associated with ageing, yet only 3% of older Canadians are aware of its most common formi Survey shows huge variance across Canada in use of simple stethoscope check to pick up characteristic ‘murmur’ of the heart valves, from 60% […]

Matinas BioPharma Announces Positive End of Phase 2 Meeting with the FDA for MAT9001 in Severe Hypertriglyceridemia (SHTG)

– FDA Agreement to Move Directly into Phase 3 – – FDA to Require a Single Phase 3 Trial of 12 Weeks Duration to Support Efficacy for an NDA filing in SHTG – BEDMINSTER, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused […]

Curi Bio Announces Mantarray™ Platform for Analysis of 3D Engineered Muscle Tissues for Discovery of New Therapeutics

SEATTLE–(BUSINESS WIRE)–Curi Bio, a leading developer of human stem cell-based platforms for drug discovery, today announced the Mantarray™ platform for human-relevant 3D engineered muscle tissue (EMT) analysis. Curi’s Mantarray platform enables the discovery, safety, and efficacy testing of new therapeutics by providing parallel analysis of 3D EMTs with adult human-like […]